EBMT 2020 | Current research in Waldenström’s macroglobulinemia
Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, outlines current research approaches in the treatment of Waldenström’s macroglobulinemia including chemotherapy-free agents and novel combinations. Dr Leblond also touches on a Phase II study evaluating first-line bortezomib, rituximab and ibrutinib in treatment-naive Waldenström’s macroglobulinemia patients (NCT03620903). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Transcript (edited for clarity)
Many trials are ongoing in US, EU and in Europe in this setting, most of the trials are chemo free treatment, combining new proteasome inhibitors, such as carfilzomib, ixazomib with rituximab or dexamethasone, or also we start in Europe first to try out combining bortezomib, rituximab and ibrutinib in naive treatment Patients with waldenström this trial is ongoing.
And also many trials are ongoing with new BTK inhibitors, zen ibrutinib, also with acalabrutinib and also some phase two with BCL-2 inhibitors as venetoclax, but all these drugs, BTK inhibitors or BCL-2 inhibitors must be given until progression so for a long time...
Many trials are ongoing in US, EU and in Europe in this setting, most of the trials are chemo free treatment, combining new proteasome inhibitors, such as carfilzomib, ixazomib with rituximab or dexamethasone, or also we start in Europe first to try out combining bortezomib, rituximab and ibrutinib in naive treatment Patients with waldenström this trial is ongoing.
And also many trials are ongoing with new BTK inhibitors, zen ibrutinib, also with acalabrutinib and also some phase two with BCL-2 inhibitors as venetoclax, but all these drugs, BTK inhibitors or BCL-2 inhibitors must be given until progression so for a long time.
So we need to design a fixed duration chemo-free trials for stopping the drugs. And this combination could be CD20 antibodies plus BTK inhibitors or BTK inhibitors plus BCL-2 inhibitors. So we need to design new trials and fixed-duration trials.
Read more...
